A patient who was discontinued from Ozempic (semaglutide) due to side effects asks: which basal insulin should be started and what initial dose is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Basal Insulin Initiation After Ozempic Discontinuation

Start with a long-acting basal insulin analog (insulin glargine or insulin degludec) at an initial dose of 10 units per day OR 0.1-0.2 units/kg/day, with glargine or degludec strongly preferred over NPH insulin due to lower hypoglycemia risk. 1, 2

Recommended Insulin Selection

Preferred basal insulins in order of preference:

  • Insulin glargine U-100 or U-300
  • Insulin degludec U-100
  • NPH insulin (only if cost is prohibitive)

Analog insulins (glargine, degludec) are superior to NPH because they have a significantly reduced incidence of hypoglycemia while maintaining equivalent glycemic control 2. The 2026 AACE guideline explicitly recommends analog insulins over NPH for this reason 2.

Initial Dosing Strategy

Base your starting dose on the patient's A1C level:

  • If A1C <8%: Start 0.1-0.2 units/kg/day (or simply 10 units/day)
  • If A1C ≥8%: Start 0.2-0.3 units/kg/day 2

Alternatively, the simpler approach is to start all patients at 10 units per day regardless of weight, which is the standard recommendation 1.

Titration Protocol

Follow this evidence-based titration schedule:

  • Set a fasting plasma glucose (FPG) goal: Target <110 mg/dL (<6.1 mmol/L) without hypoglycemia 2
  • Titration frequency:
    • Every 2-3 days for glargine
    • Every 3-5 days for degludec 2
  • Titration increments: Increase by 2 units every 3 days until FPG goal is reached 1

Alternative patient-directed titration approach:

  • Increase by 20% if FPG >180 mg/dL (>10 mmol/L)
  • Increase by 10% if FPG 140-180 mg/dL (7.8-10.0 mmol/L)
  • Increase by 1 unit if FPG 110-139 mg/dL (6.1-7.7 mmol/L) 2

Managing Hypoglycemia

If hypoglycemia occurs:

  • Reduce dose by 10-20% if FPG <70 mg/dL (<3.9 mmol/L)
  • Reduce dose by 20-40% if FPG <40 mg/dL (<2.2 mmol/L) 2
  • If no clear cause for hypoglycemia is identified, reduce dose by 10-20% 1

Critical Considerations

Discontinue sulfonylureas if the patient is taking them - after basal insulin is initiated, continuing sulfonylureas significantly increases hypoglycemia risk 2.

Consider adding back a GLP-1 RA later if glycemic targets are not met with basal insulin alone. The guidelines suggest that if A1C remains above goal on basal insulin, adding a GLP-1 RA (or using a fixed-ratio combination product like iGlarLixi or IDegLira) can be highly effective 1. This is particularly relevant since your patient was previously on semaglutide - if the side effects were dose-related gastrointestinal issues, a lower-dose GLP-1 RA in combination with basal insulin might be better tolerated than the higher doses used for monotherapy.

Timing of administration: Basal insulin can be given at any time of day, but consistency is key. Evening/bedtime dosing is traditional for NPH, but long-acting analogs like glargine can be dosed in the morning, which may actually reduce hypoglycemia risk 3.

Common Pitfalls to Avoid

  • Don't start with prandial (mealtime) insulin - basal insulin alone is the appropriate first step 1
  • Don't under-titrate - many patients remain on inadequate doses. Use the structured titration algorithms rather than making minimal adjustments 1
  • Don't continue sulfonylureas - this combination dramatically increases hypoglycemia risk 2
  • Don't use NPH if analogs are accessible - the hypoglycemia risk is substantially higher 2, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.